Pegenzileukin is under clinical development by Sanofi and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pegenzileukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pegenzileukin overview

SAR-444245 (THOR-707) is under development for the treatment of solid tumors including melanoma, metastatic melanoma, colon cancer, classic Hodgkin lymphoma (cHL), non-small cell lung cancer, thoracic cancer, skin cancer, head and neck squamous cell carcinoma, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity (mouth) cancer, malignant pleural mesothelioma, cutaneous squamous cell carcinoma (CSCC) and diffuse large B-cell lymphoma. The drug candidate is an improved version of interleukin-2. It is based on synthorx platform technology. It is administered by intravenous route.

It was also under development for the treatment of advanced unresectable or esophageal squamous cell carcinoma (ESCC), metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic hepatocellular carcinoma (HCC), metastatic colorectal cancer

Sanofi overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.

For a complete picture of Pegenzileukin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.